Detail akcie MannKind Rg online

Business Summary: MannKind Corporation is a biopharmaceutical company. It is focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Its technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices, which offers delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. Its products include Afrezza (insulin human) Inhalation Powder and the V-Go wearable insulin delivery device. The Afrezza (insulin human) Inhalation Powder is an inhaled insulin indicated to enhance glycemic control in adults with diabetes. The V-Go wearable insulin delivery device provides subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease pipeline includes Tyvaso DPI (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Financial Summary: BRIEF: For the nine months ended 30 September 2024, MannKind Corp revenues increased 49% to $208.7M. Net income totaled $20.2M vs. loss of $13.3M. Revenues reflect Product sales segment increase of 50% to $132.9M, Royalties segment increase of 48% to $75.3M, United States segment increase from $99.9M to $208.7M. Net Income reflects United States segment income increase from $6.8M to $46.1M.